Etoposide

For research use only.

Catalog No.S1225 Synonyms: VP-16, VP-16213

135 publications

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity. Etoposide induces autophagy, mitophagy and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Etoposide has been cited by 135 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity. Etoposide induces autophagy, mitophagy and apoptosis.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NH\QRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDoTWM2OD1yLkGy5qCKyrIkgJmwMlAyKM7:TR?= NInWSnczPTl4MEK4Ni=>
KellyCis83 MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjwdppKSzVyPUCuNVbjiIoEsfMAjVAvODJizszN MYWyOVk3ODJ6Mh?=
SK-N-AS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjPdW5KSzVyPUCuNlTjiIoEsfMAjVAvODNizszN NFnKTnczPTl4MEK4Ni=>
SK-N-ASCis24 NYrjd2FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nZU2lEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= NYe0bHVEOjV7NkCyPFI>
U87 NIHkNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnvcFUxNTVyIN88US=> Mo[5OFghcA>? MlLT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfobYNpKGOjbjDi[UBmdmijbnPl[EBjgSC|aXzpZolvcW5? NFfaPFUzPTd3MEK3Ny=>
HCT116 NEexdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT6XmgxNjVvMj61JO69VQ>? NXq1U3dlPDkEoHlCpC=> NWfFb|RvUUN3ME2xMlc{yqEEsdMgNE4zOcLizszN NXThUIF3OjV5NE[3OlM>
HT-29 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWiwMlUuOi53IN88US=> MWO0POKhcMLi NUPTSIt{UUN3ME23MlLDqMLzwrCxMlA1yqEQvF2= MmG4NlU4PDZ5NkO=
Caco2 M4ftVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf4NE42NTJwNTFOwG0> M2r2eVQ5yqCqwrC= M{PNc2lEPTB;Nz6yOuKhyrIEoEGuOljDqM7:TR?= MWSyOVc1Pjd4Mx?=
COLO 205 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPMNE42NTJwNTFOwG0> NXT4OXl7PDkEoHlCpC=> M365TWlEPTB;MT62NeKhyrIEoECuNFLDqM7:TR?= MlvrNlU4PDZ5NkO=
SW480 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfzOpcxOC53LUKuOUDPxE1? MXK0POKhcMLi NXLoV3B3UUN3ME20MlkzyqEEsdMgNE4{O8LizszN MmDpNlU4PDZ5NkO=
HEK293T MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L1NFEuPSEQvF2= NXGyfXVOPDkEoHlCpC=> MlvqTWM2OD1{LkSyxsDDucLiMD6wOeKh|ryP MUiyOVc1Pjd4Mx?=
Hep3B  MXvGeY5kfGmxbjDBd5NigQ>? NIP5W4MyOCEQvF2= MUG0POKhcMLi MonudoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> M1fQS|I2PjN|NU[0
Hep3B  MVXGeY5kfGmxbjDBd5NigQ>? NEDyTWMxNjFvMUCg{txO MkL3NlQhcA>? MVnzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? NGrQWZczPTZ|M{W2OC=>
HEK293 NUHiTJR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzvcXlKSzVyPUeuNVTDqMLzwrCwMlM3yqEQvF2= NYnB[pdvOjV4MEOxNlI>
DU145 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rhemlEPTB;Mj6yPOKhyrIEoECuNFTDqM7:TR?= MYKyOVYxOzF{Mh?=
HCT15 M3zmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwOEJCpOKyyqByLkCxxsDPxE1? NW\rZnkzOjV4MEOxNlI>
T47D NELFWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNwMUlCpOKyyqByLkGxxsDPxE1? NF;YOmIzPTZyM{GyNi=>
SMMC-7721 NXHPTWJITnWwY4Tpc44hSXO|YYm= Mn\pOFAh|ryP NVvUbGM6PDhiaB?= MnvoSG1UVw>? NU\zNmw3cW6mdXPld{DPu0h{QWig[o9kcSCob4LtZZRqd25? M12wfFI2PTR2M{[x
MDA-MB-231 NVLGO4dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W2O|czyqCq MnLlTWM2OD1{MT6yxsDDucLiND6yxsDPxE1? M1j6WlI2PDh4MkG5
MCF-7 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnjdVFKPzMEoHi= NUTZUGExUUN3ME2xNE46yqEEsdMgNk4yyqEQvF2= NHPST4kzPTR6NkKxPS=>
Jurkat M4r2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vIOVczyqCq MojYTWM2OD1zLkNCpOKyyqBzLkZCpO69VQ>? NED4R3QzPTR6NkKxPS=>
HeLa MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe3NuKhcA>? NXXI[G9WUUN3ME2zMlnDqMLzwrCyMlPDqM7:TR?= MkPUNlU1QDZ{MUm=
MCF7  MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVq1MVExOCEQvF2= MkXOO{Bl M1HyUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnK3NlU1PzJ4MUm=
K562 NXjDTFFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf4O|LDqGh? MmXlTWM2OD1yLkK5xsDPxE1? NEXBO2wzPTJ6Mk[1Ny=>
K/VP.5 NWrZZXh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPRO|LDqGh? NIfYSVVKSzVyPUSuPeKh|ryP NWfqfINEOjV{OEK2OVM>
SH-EP  MYjGeY5kfGmxbjDBd5NigQ>? MVSyNOKh|rypL33s MmfnNlTDqGh? Ml[wbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIVv\G:pZX7veZMhTEWSUB?= MmLDNlUzPjF7OEG=
SCC25 NYDGeodtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Hzd|I1yqCq NWPVUIZUUUN3ME20N{4{yqEEsdMgNU4yOsLizszN M1fVPVI2OjJyN{K5
CAL27 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOyOOKhcA>? M3G1UmlEPTB;NUKuNeKhyrIEoEGuNFnDqM7:TR?= NV72SXhPOjV{MkC3Nlk>
FaDu NYPmXII3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOyOOKhcA>? NF\URXdKSzVyPUK1Mlg6yqEEsdMgNU4yO8LizszN MnfINlUzOjB5Mkm=
SCC25 M4Xr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W0cFQ5yqCq M{DBbmlEPTB;MkCuPFbDqMLzwrCxMlA4yqEQvF2= NUiwZ3FqOjV{MkC3Nlk>
CAL27 NHPPXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfSOXA1QMLiaB?= MV3JR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP MXOyOVIzODd{OR?=
FaDu NX63Xm5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HsbVQ5yqCq MlznTWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP M2PiW|I2OjJyN{K5
SCC25 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3GdJM4OsLiaB?= NGO2bYRKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= M1fjWFI2OjJyN{K5
CAL27 M3XhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfLSWw4OsLiaB?= M3;NS2lEPTB;ND6yO:KhyrIEoEGuNVTDqM7:TR?= NIjGeWozPTJ{MEeyPS=>
FaDu NUPJcodNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;TUZc4OsLiaB?= MkHqTWM2OD13LkCyxsDDucLiMT6xOeKh|ryP NEi3cGUzPTJ{MEeyPS=>
MCF-7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXi0POKhcMLi NE\2bFdFVVOR M4fzXmlEPTB;Nz6yxsDDucLiMD64xsDPxE1? M1i0O|I2OjF4M{e4
T-47D Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu0RZI1QMLiaNMg NVzmNWxoTE2VTx?= M4LZVGlEPTB;Nz63xsDDucLiMD63xsDPxE1? MUSyOVIyPjN5OB?=
MDA-MB-231 NWD1dnNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\pOFjDqGkEoB?= MXrEUXNQ M4HMZmlEPTB;MUKuPOKhyrIEoEGuNOKh|ryP NFqybVYzPTJzNkO3PC=>
DU145 Ml\qRZBweHSxc3nzJGF{e2G7 NFfSeHcyOC1zMECg{txO MkGxPEBp MmfNSG1UVw>? MXvpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NH7VRVEzPTF2OU[4NS=>
DU145 stem-like NXLkfohLSXCxcITvd4l{KEG|c3H5 MUOxNE0yODBizszN M4LNNVghcA>? MXTEUXNQ MWfpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYfSU2U{OjVzNEm2PFE>
DU145 NEPFSIlHfW6ldHnvckBCe3OjeR?= NF\zR4cyOC1zMECg{txO MVmyJIg> MXTEUXNQ NUDkbnM{cW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXWyOVE1QTZ6MR?=
DU145 stem-like MVfGeY5kfGmxbjDBd5NigQ>? MXSxNE0yODBizszN NWS5SFZyOiCq MnyxSG1UVw>? MkP5bY5kemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGGwZDDk[YNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1rVclI2OTR7Nkix
UW228-3 NH;lXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmSyNE4xOS1|MECg{txO NHexWFM1QCCq MYHEUXNQ NFH3e|ZKSzVyPUCuPVnDqM7:TR?= M{j5TVI2OTF7MUi1
NSCs NUHsdXJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fsbFAvODFvM{CwJO69VQ>? M1;WW|Q5KGh? NVTvUXlJTE2VTx?= M1zHd2lEPTB;MD6zMVPDqM7:TR?= MWmyOVEyQTF6NR?=
MKL-1  MXLGeY5kfGmxbjDBd5NigQ>? M3rVXVExNTFyMECgcm0> MYG0JIQ> NYHwV4tbcW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= NYrT[|J{OjVzMU[3OVQ>
MCF7 EV NFjucohHfW6ldHnvckBCe3OjeR?= MUCxNE0yODBizszN NX3YbVhNOuLCiXi= M{PUeIlv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ MkXJNlUxQDh{MEO=
MCF 7BMI1 NGrXZVBHfW6ldHnvckBCe3OjeR?= MV:xNE0yODBizszN NGDJ[HEz6oDLaB?= M1HqOIlv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ M1vZTVI2ODh6MkCz
MCF7 EV MYjGeY5kfGmxbjDBd5NigQ>? MYCxNE0yODBizszN NFe1bIUz6oDLaB?= MmLTSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u MlTlNlUxQDh{MEO=
MCF7 BMI1 M2e4RmZ2dmO2aX;uJGF{e2G7 MnW0NVAuOTByIN88US=> NWqwUJRvOuLCiXi= NYTmPFFxTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v NH3KdmIzPTB6OEKwNy=>
HepG2 NV\2NJFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfEUXNQyqB? NYHpcWJpUUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> MlywNlUxPzh|MUG=
MOLT-3 MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fmR2ROW00EoB?= M17ucmlEPTB;MD6wOVHDqMLzwrCwMlAxOsLizszN MVyyOVA4QDNzMR?=
HT1080 NYHJUm1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofXNU0yODBizszN NFjQS5Y1NzJ2L{S4JIg> NGfyc2xFVVORwrC= MULpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NYPDeXdtOjVyN{iwOlQ>
HT1080 MXfGeY5kfGmxbjDBd5NigQ>? NGm1RmQxNjByMEGtNVAxKM7:TR?= MmLkNU0zPCCq MnXKSG1UV8Li NIjkbYJqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MmjuNlUxPzhyNkS=
HT1080 NGm5[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln0NE4xODBzLUGwNEDPxE1? NVfUXlRqOjRiaB?= MmfpSG1UV8Li NEjid4lk[XW|ZYOgZY4hcW6lcnXhd4UhcW5idHjlJI52dWKncjDv[kBk\WyuczDpckBIOi:PLDD3bIlt\SCmZXPy[YF{cW6pIGOgZY5lKEdzIIDoZZNmKGOnbHzz MVOyOVA4QDB4NB?=
HD-MY-Z Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDvO4ZQOjRxNEivO|IhcA>? NI\hPJlKSzVy78{eNVAxKM7:TR?= MWiyOVA1QDJ|Nh?=
DOHH-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XiXVI1KGh? NV;F[3RxUUN3MP-8olExOCEQvF2= NVHUd5ZjOjVyNEiyN|Y>
DOHH-2 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HJOVQ5KGh? NELoeFhKSzVyPUG5MlnDqM7:TR?= Moq3NlUxPDh{M{[=
DOHH-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYe3NkBp MoPsTWM2OD13wrFOwG0> NWSwZ|V6OjVyNEiyN|Y>
REH NHrMc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PBUlI1KGh? NFLiU5RKSzVyPUCuNFI4yqEQvF2= MW[yOVA1QDJ|Nh?=
REH M4O1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn6RpU1QCCq NHTBXpFKSzVyPUCuNFE1yqEQvF2= MY[yOVA1QDJ|Nh?=
REH Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXYO|IhcA>? NH7LZ3lKSzVyPUCuNFE2yqEQvF2= M3Lx[lI2ODR6MkO2
HH NHjDXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrVd3IzPCCq MWPJR|UxRTFyND63xsDPxE1? MnvzNlUxPDh{M{[=
HH MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7wcoE1QCCq MlLGTWM2OD12OD62xsDPxE1? MXGyOVA1QDJ|Nh?=
HH M1XabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjCTHo4OiCq NFzsO49KSzVyPUG0MlfDqM7:TR?= MljTNlUxPDh{M{[=
HuT-78 NFrOdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jRfVI1KGh? NEPpZ3pKSzVyPUmuN:Kh|ryP MlHpNlUxPDh{M{[=
HuT-78 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjYSYpzPDhiaB?= NWLTSot[UUN3ME20MlPDqM7:TR?= NGrudpkzPTB2OEKzOi=>
HuT-78 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SzSlczKGh? Ml71TWM2OD12LkNCpO69VQ>? M1\1ZlI2ODR6MkO2
OPM-2 M2rUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fSTlI1KGh? NUKxdm1mUUN3ME2yOE4yyqEQvF2= MlXWNlUxPDh{M{[=
OPM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvpfHJqPDhiaB?= NGXzNHlKSzVyPUVCpO69VQ>? Mn;mNlUxPDh{M{[=
OPM-2 NVrjUmZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q0VlczKGh? NWTmWXJYUUN3ME2xMlPDqM7:TR?= MmT3NlUxPDh{M{[=
RPMI-8226 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW2Zo8zPCCq MkLUTWM2OD1zME[uOuKh|ryP MnOyNlUxPDh{M{[=
RPMI-8226 NUTYflM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYK0PEBp NWrBUXhLUUN3ME25NU4yyqEQvF2= M4LNbFI2ODR6MkO2
RPMI-8226 NF3DdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX73V5MyPzJiaB?= Mmr0TWM2OD1zND65xsDPxE1? NXLhWGZsOjVyNEiyN|Y>
U-266 M4XFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqyOEBp NHnw[nNKSzVyPUi2MlLDqM7:TR?= MYSyOVA1QDJ|Nh?=
U-266 M3q4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm0PEBp NY[yRY5nUUN3ME22PE41yqEQvF2= NHq2XVgzPTB2OEKzOi=>
U-266 NVvY[FVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK3NJM4OiCq MlzRTWM2OD1{Nz60xsDPxE1? MlzONlUxPDh{M{[=
Kelly NYruSHBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXUNE0yOCEQvF2= M1nYVlczyqCq MWPJR|UxRTFwNUG4xsDPxE1? NXH2Tmw3OjVyMEi5NFA>
SH-SY5Y  MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjZVYxSOC1zMDFOwG0> MVq3NuKhcA>? NEPyd5dKSzVyPUCuO|U1yqEQvF5CpC=> M3fYbFI2ODB6OUCw
SK-N-AS MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX5c44xNTFyIN88US=> M3\6VVczyqCq NE\TZZFKSzVyPUGuO|EzyqEQvF5CpC=> NVTWN3NuOjVyMEi5NFA>
SK-N-DZ NXviOJdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7GdlZwOC1zMDFOwG0> NIPnboU4OsLiaB?= M2G2XWlEPTB;NT60PFXDqM7:TR?= MUOyOVAxQDlyMB?=
HepG2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;QWlQ5yqCq M{i0NWROW00EoB?= MlPzTWM2OD1zMz62OeKhyrIEoECuPVLDqM7:TR?= MkjzNlQ6QTZzM{[=
A549 M3znUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:xRoRNPDkEoHi= NVHIU4hGTE2VT9Mg MWTJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= NF;rb|YzPDl7NkGzOi=>
MCF7 M{fXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWi0POKhcA>? MXzEUXNQyqB? NV32dWZXUUN3ME24NU4xQcLiwsJCpFE1NjJzwrFOwG0> NV\EeWtQOjR7OU[xN|Y>
HL-60  NWH2bm1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jVVFczyqCq M1XINGlEPTB;MD6xNwKBjc7:TR?= MlywNlQ6QTNyMUS=
HL-60[R] M1v4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rHRlczyqCq NYrS[XhqUUN3ME2zMlEz6oDHzszN M4jSVFI1QTl|MEG0
MIAPACA M17zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjHTVUxRTFwMzFCtUAxNjB|IN88US=> NU\SXVlPOjR7NUO4NlE>
MCF-7 M4PKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXibIZkT0l3ME2wMlI2KMLzIECuNUDPxE1? MYOyOFk2Ozh{MR?=
HeLa M4fufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7iSJlUT0l3ME2wMlY1KMLzIECuOEDPxE1? NUPxdIFjOjR7NUO4NlE>
MO59K  NIXobFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3BO{Bl MmjVTWM2OD1yLkG35qCG|ryP M3\Od|I1QTV|NU[x
MO59J NF;LZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnaOFI4KGR? MnHCTWM2OD1yLkJihKXPxE1? MYmyOFk2OzV4MR?=
ME 180 M3vnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVW0POKhcMLi NH6wfG9KSzVyPUiuPeKhyrIEoECuN-KBjc7:TR?= M2jhZlI1QTV|MEK3
MCF-7 NFz1O2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm2eIU1QMLiaNMg M2DkbWlEPTB;MkOuPUDDuSByLkRihKXPxE1? MXKyOFk2OzB{Nx?=
HeLa MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\2OFjDqGkEoB?= NYrMOmRoUUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= NYfLVppqOjR7NUOwNlc>
MDA-MB-453 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXThZ|FkPDkEoHlCpC=> MlXQTWM2OD1zMj61JOKyKDBwOEZihKXPxE1? M4q3RlI1QTV|MEK3
MDA-MB-231 NUjVSGtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPwOFjDqGkEoB?= M3\KUWlEPTB;MkSuNlIhyrFiMj65OQKBjc7:TR?= MYqyOFk2OzB{Nx?=
PC-3 NED2bmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe0POKhcMLi NH3scFNKSzVyPUG0MlQhyrFiMz6yN-KBjc7:TR?= M1zoNlI1QTV|MEK3
HT-29 NXS5bZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHPXnNxPDkEoHlCpC=> MlzPTWM2OD1{MT60OUDDuSB|Lki35qCG|ryP Mny0NlQ6PTNyMke=
BGC-823 M1rCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPmTm81QMLiaNMg M1zxc2lEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= MUGyOFc6Ozh5Nx?=
HeLa MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfkW|R[PDkEoHlCpC=> NXvtUYtGUUN3ME2yNFkvQTBiwsGgNVMvPDJi4pEF{txO NH\0TnUzPDd7M{i3Oy=>
A549 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonSOFjDqGkEoB?= MmHSTWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= NFmwOWUzPDd7M{i3Oy=>
HK-2 M3\hbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LBSVQ5yqCqwrC= NGTRWoFKSzVyPUmuNVchyrFiMT61PQKBjc7:TR?= MWCyOFc6Ozh5Nx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
- Collapse

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
- Collapse
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213
Smiles COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(OC4OC5COC(C)OC5C(O)C4O)C6=C2C=C7OCOC7=C6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03305341 Active not recruiting Drug: NDA Etoposide - study|Drug: NDA Etoposide - usual Small Cell Lung Cancer Han Xu M.D. Ph.D. Sponsor-Investigator IRB Chair|Medicine Invention Design Inc December 18 2018 Phase 3
NCT03264131 Recruiting Drug: Brentuximab Vedotin|Drug: CHEP Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases UNC Lineberger Comprehensive Cancer Center|Seattle Genetics Inc. October 15 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID